Company Overview
Savara Inc. operates as a clinical stage biopharmaceutical entity dedicated to addressing rare respiratory diseases within the United States market. The company's core operational focus centers on its lead product candidate, molgramostim, which functions as an inhaled granulocyte-macrophage colony-stimulating factor currently undergoing Phase 3 development specifically for the treatment of autoimmune conditions. This business model places the firm firmly within the Healthcare sector and the specialized Biotechnology industry, where capital intensity and lengthy development cycles are standard operational characteristics. With a market capitalization of $1.03B and an employee base of 70, the company demonstrates a capital-efficient structure typical of early-to-mid-stage biotech firms that prioritize research and development over broad commercialization. The valuation indicates that the market assigns significant worth to the potential future commercialization of molgramostim, despite the absence of current revenue streams, reflecting a premium placed on intellectual property and clinical trial progress rather than existing cash flows.
Financial Health
The company reports net income of $-118,837,000 over the trailing twelve months, while revenue and EBITDA figures are not currently available for disclosure. The substantial gap between reported revenue and net income, evidenced by the negative net income despite the lack of stated revenue, reveals a cost structure dominated by research, development, and operational expenses that far exceed any current sales generated. Free cash flow stands at $-55,517,876, which indicates that the company is burning cash to fund its clinical programs and cannot currently support significant capital expenditures or expansion without external financing. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which signifies that the company has not yet achieved commercial profitability or that revenue is insufficient to cover direct costs and operating expenses to generate a positive margin. The balance sheet shows cash reserves of $236.59M against total debt of $29.91M, resulting in a debt-to-equity ratio of 14.73; while the absolute debt level is low, the high ratio relative to equity suggests a capital structure heavily reliant on equity financing or warrant exercises to manage liabilities. The current ratio is listed at 11.85, a figure that indicates exceptionally strong short-term liquidity relative to current liabilities, suggesting the company has ample resources to meet its obligations in the immediate term. Return on Equity is -63.4% and Return on Assets is -32.9%, metrics that reveal that management is currently deploying capital to generate negative returns, a common trajectory for clinical-stage companies where assets are tied up in intangible research projects rather than profit-generating operations.
Valuation Assessment
The trailing P/E ratio is not available due to the lack of net income, while the forward P/E is -15.80, a negative figure that implies the market is pricing the stock based on anticipated future earnings recovery or significant capital raises rather than current profitability. The price-to-book ratio stands at 6.30, indicating that the market values the company at a significant premium over its net asset value, likely driven by the perceived potential of the molgramostim asset pipeline and the strategic importance of its intellectual property. Alternative valuation metrics such as the EV/EBITDA of -8.55 and the unavailable price-to-sales ratio further highlight that traditional earnings-based valuation models are not applicable, as the company is not yet generating positive earnings or sales volume comparable to its enterprise value. The stock has traded between a 52-week low of $1.89 and a 52-week high of $7.00, with the current valuation positioned within this historical range reflecting volatility driven by clinical trial milestones and regulatory news. A beta of 0.26 suggests that the stock exhibits low volatility relative to the broader market, moving less than the market average in response to general economic shifts or sector-wide fluctuations.
Growth & Income
Revenue growth and earnings growth rates are both unavailable for the trailing twelve months, which prevents a direct comparison of whether earnings are growing faster or slower than revenue at this specific point in the company's lifecycle. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the entity retains all available capital to fund its clinical trials and operational needs rather than distributing income to shareholders. Consequently, the company reinvests its entire financial position, including its cash reserves, into growth initiatives such as advancing molgramostim through Phase 3 development to secure regulatory approval and commercial launch. The overall growth and income profile is characterized by a complete reliance on future clinical success and potential product commercialization, with no current income generation to support shareholder distributions or organic revenue expansion.